View all Conferences
View all ILC Conferences

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

15th Annual International Lung Cancer Congress®

Add this event to my calendar:
PER Practice Pulse
Lung: Practice Pattern Questions
How frequently do you recommend a platinum doublet (e.g., pemetrexed/carboplatin or paclitaxel/carboplatin) in patients with advanced NSCLC and a PS of 2?


The International Lung Cancer Congress® provides current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies that will shape the future of lung cancer therapy. Leading international and national faculty will address critical topics in lung cancer staging, personalized therapy, and the latest clinical data impacting the treatment of lung cancer. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management. The meeting also includes a recurring session that highlights clinical research activity of Cooperative Groups in the United States, Europe, and Asia.


Target Audience

This educational activity is directed toward medical, surgical and radiation oncologists interested in the treatment of patients with lung cancer.  Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.

Click here to download brochure

Educational Objectives

  • Compare and contrast the clinical outcomes of first- and second-generation EGFR inhibitors and ALK inhibitors for NSCLC patients across all lines of therapy
  • Summarize guidelines from CAP, ASCO, and NCCN regarding both mutational analysis and use of molecularly targeted agents for patients with NSCLC
  • Evaluate data on new agents and approaches in development for lung cancer
  • Review recent data on immune-checkpoint inhibition with anti-PD-1, anti-PD-L1, and anti-CTLA-4 blockade
  • Assess how emerging data on the use of molecularly targeted agents can be used to improve the treatment of patients with NSCLC
  • Describe the NSCLC maintenance therapy standards of care and current options for improved patient outcomes applying multi-targeted antifolate, anti-angiogenesis and anti-EGFR strategies
  • Summarize the factors to be considered when making treatment sequencing decisions, including efficacy of a drug at different stages, prior therapies, existing comorbidities, disease characteristics, and the need for molecular testing

The International Lung Cancer Congress® is endorsed by:
IASLC is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association's membership includes more than 3,000 lung cancer specialists in 80 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public.

BJALCF is the first international collaborative entity of its kind, raising over $6 million for Lung Cancer research. BJALCF's focus is on projects promising progress through early detection, genetic testing, and drug discovery with patient-focused outcomes. Their ultimate goal is to increase the low survival rate of lung cancer by becoming the largest source of non-profit funding dedicated to turning lung cancer into a manageable chronic disease. Since 2008, BJALCF has sponsored a key-note address and provided overall support of the International Lung Cancer Congress.


Our Mission       |      Accreditation       |      Privacy Policy       |      Terms & Conditions of Use       |      Contact PER®
Copyright © 2014 Physicians' Education Resource®, LLC. All rights reserved.
Contact PER®
Physicians' Education Resource®, LLC
666 Plainsboro Rd. Suite 356
Plainsboro, NJ 08536

Phone (609) 378-3701
Fax (609) 257-0705